The Drugs That Could Cure Coronavirus
The global health apparatus is working overtime diagnosing, tracking, and treating those infected with the Covid-19 coronavirus. One analyst on Wall Street is working overtime too: Evercore ISI analyst Josh Schimmer updated clients on Sunday, suggesting some out-of-the-box ideas for coronavirus treatment.
“We are pivoting from tracking the Covid calamity,” Schimmer wrote in his Sunday research report. “To anticipating news flow from biopharma as the field scrambles to develop countermeasures in the hopes of enabling a V-shaped correction.”
V-shaped refers to a best-case scenario where recovery rates soar, disease mortality falls, and fears subside quickly.
So far, Schimmer says, investors have focused on the Gilead Sciences (ticker: GILD) product Remdesivir. But the product isn’t approved yet. It is an “investigational nucleotide analog with broad-spectrum antiviral activity.”
That’s a mouthful, but nucleotide analogues are used to inhibit viral replication in infected cells. A study for treating Covid-19 with Remdesivir began enrolling in Nebraska in late February. Gilead is moving as fast as it can.